The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial recommendation to not consider deutetrabenazine as a new active substance. In June this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback